Efficacy of Early Treatment with Favipiravir on Disease Progression among High Risk COVID-19 Patients: A Randomized, Open-Label Clinical Trial.
Chuan Huan ChuahTing Soo ChowChee Peng HorJoo Thye ChengHong Bee KerHeng Gee LeeKok Soon LeeNoridah NordinTiang Koi NgMasliza ZaidNor Zaila ZaidanSuhaila Abdul WahabNurul Ashikin AdnanNoorlina NordinTze Yuan TeeSu Miin OngSuresh Kumar ChidambaramMahiran MustafaPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)
Among COVID-19 patients at high risk of disease progression, early treatment with oral favipiravir did not prevent their disease progression from non-hypoxia to hypoxia.